Altum Sequencing Named Overall Winner of Alhambra Venture 2026

Precision oncology company adds another award to a strong run of recognitions, reinforcing confidence in its liquid biopsy technology

Altum Sequencing has been named the overall winner of Alhambra Venture 2026, one of Spain's leading startup events, marking another milestone in a period of sustained recognition for the company.

Independent Validation of a Growing Need

Receiving this recognition from one of Spain's leading startup platforms is an encouraging signal that precision oncology and ultra-sensitive liquid biopsy are addressing a real and growing clinical need.

Over the past few weeks, Altum Sequencing has also been recognized at South Summit and The Ventures. While awards are never the goal, independent recognition from different expert juries reinforces the company's conviction that it is building technology with the potential to make a meaningful impact in cancer diagnostics.

Representing Altum on Stage

Altum Sequencing extends its thanks to Alhambra Venture and the jury for this recognition. Isabel Espejo Díaz, PhD, represented Altum on stage during the competition, while Dr. Marta Dueñas accepted the award on the company's behalf.

Focus Remains on Execution

For Altum Sequencing, this latest recognition reinforces a broader focus: generating clinical evidence, expanding collaborations with leading hospitals and pharmaceutical companies, and continuing to build the future of molecular disease monitoring.

As the company's CEO has noted, the real milestone is not winning awards — it is bringing better diagnostics to patients.

A Pattern of Recognition

Alhambra Venture adds to a growing list of recognitions for Altum Sequencing, following closely on its awards at South Summit and The Ventures Spain. Together, these milestones reflect increasing validation — from investors, juries, and the broader innovation ecosystem — of Altum's mission to transform cancer monitoring through precision molecular technology.

Altum Sequencing is a precision oncology company based in Madrid, Spain, developing ctDNA-based liquid biopsy technology for cancer monitoring. Spun off from Hospital Universitario 12 de Octubre, the company's platform supports minimal residual disease detection and longitudinal treatment monitoring across a range of oncology indications.

#HuntingCancer #CancerMonitoring #LiquidBiopsy